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Abstract
Purpose The primary purpose of this study was to dem-
onstrate intraobserver/interobserver reproducibility for
novel semiautomated measurements of hepatic volume used
for Yttrium-90 dose calculations as well as whole-liver and
necrotic-liver (hypodense/nonenhancing) tumor volume
after radioembolization. The secondary aim was to provide
initial comparisons of tumor volumetric measurements with
linear measurements, as deﬁned by Response Evaluation
Criteria in Solid Tumors criteria, and survival outcomes.
Methods Between 2006 and 2009, 23 consecutive radio-
embolization procedures were performed for 14 cases of
hepatocellular carcinoma and 9 cases of hepatic metastases.
Baseline and follow-up computed tomography obtained
1 month after treatment were retrospectively analyzed.
Three observers measured liver, whole-tumor, and tumor-
necrosis volumes twice using semiautomated software.
Results Good intraobserver/interobserver reproducibility
was demonstrated (intraclass correlation [ICC][0.9) for
tumor and liver volumes. Semiautomated measurements of
liver volumes were statistically similar to those obtained
with manual tracing (ICC = 0.868), but they required sig-
niﬁcantly less time to perform (p\0.0001, ICC = 0.088).
There was a positive association between change in linear
tumor measurements and whole-tumor volume (p\
0.0001). However, linear measurements did not correlate
with volume of necrosis (p[0.05). Dose, change in tumor
diameters, tumor volume, and necrotic volume did not cor-
relate with survival (p[0.05 in all instances). However,
Kaplan–Meier curves suggest that a [10% increase in
necrotic volume correlated with survival (p = 0.0472).
Conclusion Semiautomated volumetric analysis of liver,
whole-tumor, and tumor-necrosis volume can be performed
with good intraobserver/interobserver reproducibility. In
this small retrospective study, measurements of tumor
necrosis were suggested to correlate with survival.
Keywords Radioembolization   CT   Volume  
Tumor   Response   Necrosis
Introduction
Dose calculations for radioembolization using Yttrium-90
(
90Y) microspheres, i.e., Theraspheres (MDS Nordion,
Ottawa, Ontario, Canada) and Sirspheres (Sirtex Medical,
Wilmington, MA), require calculation of liver volume and
estimation of tumor burden [1]. A number of techniques
have been described to determine liver volume for planning
liver transplant. Volumetric measurements of tumors and
organs, as seen on computed tomography (CT) images, are
W. L. Monsky (&)   S. Loh   J. Fisher   P. Sandhu  
V. Sidhar   A. J. Chaudhari   F. Lin   L.-S. Deutsch  
R. D. Badawi
Department of Radiology, University of California Davis
Medical Center, 4860 Y Street, Ste. 3100, Sacramento,
CA 95817, USA
e-mail: wayne.monsky@ucdmc.ucdavis.edu
A. S. Garza   I. Kim
University of California Davis Medical School,
Sacramento, CA 95817, USA
T.-C. Lin
Department of Statistics, University of California Davis,
Davis, CA 95616, USA
C.-S. Li
Division of Biostatistics, Department of Public Health Services,
University of California Davis, Davis, CA 95616, USA
123
Cardiovasc Intervent Radiol (2011) 34:306–318
DOI 10.1007/s00270-010-9938-3often performed by manual tracing of the organ boundary
and summation of the liver area on each section, taking into
account the thickness of each image slice. However, the
manual tracing process is time consuming [2, 3] and
arguably unreliable and inaccurate because it is highly
operator dependent. Techniques for the automated deter-
mination of liver volumes could aid in planning the
90Y
dose for the treatment of hepatic tumors.
Furthermore, response to these local regional therapies
can be assessed using semiautomated segmentation. The
technique can be used to determine the change in volume of
necrotic and viable tumor. However, these techniques must
ﬁrst be validated, and interobserver/intraobserver repro-
ducibility must be demonstrated. These volumetric analyses
should be compared with Response Evaluation Criteria in
Solid Tumors (RECIST) criteria, the current standard for
tumor response assessment, to suggest clinical applicability.
Moreover, to be clinically useful, tumor response analysis
should provide an early indicator of survival outcomes.
In the recent RECIST 1.1 criteria, it was recognized that
volumetrictechniquesmayimproveonthecurrentstandardof
single long-axis tumor measurements, which may be inade-
quate for evaluatingtumorresponseafterbiologic, cytostatic,
and local regional therapies [4]. Tumor-response measure-
ments described by RECIST criteria evaluate only unidi-
mensional tumor measurements and disregard the extent of
necrosis, which includes the initial effect of all local regional
therapies. In one study, RECIST criteria missed all complete
responses and underestimated the extent of partial tumor
responsebecauseoftissuenecrosis,thusincorrectlyassessing
the therapeutic efﬁcacy of local regional therapy [5].
European Association for the Study of the Liver (EASL)
guidelines recommended that assessment of tumor response
should incorporate the decrease in viable tumor burden and
that tumor necrosis should be measured when evaluating
therapeuticresponseinhepatictumors.Thesemeasurements
are usually based on linear measurements of the tumor and
necrosis. Contrast-enhanced and diffusion-weighted mag-
netic resonance imaging (MRI) has been used to evaluate
tumor necrosis after catheter-directed local regional thera-
pies [6]. Tumor necrosis is often patchy and irregular,
making linear measurements difﬁcult and more susceptible
to observer-based error as well as poor measurement
reproducibility. The computer-assisted semiautomated seg-
mentation and volumetric analysis techniques we describe
heremayimprovemeasurementreproducibility,particularly
when measuring complex and patchy tumor necrosis and
enhancement. This volumetric analysis of tumor necrosis
could provide an earlier indication of therapeutic efﬁcacy.
Volumetric tumor response has been applied to lung
tumors and lymphoma [7]. Few studies have evaluated
volumetric techniques for the assessment of hepatic tumors
[8]. Volumetric segmentation techniques have not been
applied to response assessment after local regional thera-
pies, such as radioembolization and chemoembolization.
The purpose of this study was ﬁrst to demonstrate good
interobserver/intraobserver reproducibility when measur-
ing liver volume for treatment planning as well as when
measuring viable and necrotic, hypodense tumor after local
regional therapy. Changes in whole-tumor and necrotic-
tumor volume were then compared with linear measure-
ments, as described by RECIST criteria, to determine any
association. Finally, in this small pilot study, these mea-
surements were compared with patient survival to provide
proof of the principle that they might be used as early
imaging end points for tumor-response assessment.
Materials and Methods
Subject Demographics
The study was a cohort study in which volumetric analysis
techniques were applied in retrospective fashion to CT
images obtained during the course of previous radioemb-
olization treatments. Institutional Review Board (IRB)
approval for the study was obtained. Data collection was
performed in accordance with Health Insurance Portability
and Accountability Act regulations.
Subjects were consecutive patients who had undergone
radioembolization for HCC as well as hepatic metastases
between 2006 and 2009 according to a protocol approved by
our IRB. The study population comprised 18 men (mean age
66.1 years[range48–79])and5women(meanage67.3 years
[range 60–73]). Fourteen patients had a known diagnosis of
hepatocellularcarcinoma.Theremainingpatientshadknown
metastasis to the liver, of which metastatic colon carcinoma
was the most prevalent (5 cases), followed by metastatic
carcinoid (2 cases), metastatic insulinoma (1 case), and
metastatic leiomyosarcoma (1 case). The number of tumors
per individual patient ranged between 3 and 12. Long-axis
measurements for the tumors ranged between 1.2 and 18 cm
(mean9.8[SD6.9]).Iftumorsoccupiedboththerightandleft
lobes of the liver, lobar treatment was performed with sepa-
rate procedures approximately 1 month apart. In 2 patients,
both lobes were treated twice. In these cases, ‘‘baseline’’
measurements were made using the CT image obtained
within 1 month before a given treatment.
All patients underwent pretreatment assessment con-
sisting of a clinical history, appropriate laboratory workup,
and baseline four-phase liver CT image obtained within
1 month of treatment. The selection of
90Y over other
treatments was based on the consensus of a multidisci-
plinary team during tumor board conferences at our insti-
tution and in accordance with our inclusion and exclusion
criteria (Table 1). No systemic therapy was administered
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123once radioembolization was initiated. Sixteen of these
patients had previously progressed with ﬁrst- or second-
line chemotherapy. Patients were seen in the follow-up
clinic at 1 week, 1 month, and then at 3-month intervals
while they underwent local regional therapy.
Radioembolization Procedure
The technical details for radioembolization have previously
been described [1]. All patients underwent mapping angi-
ography before treatment to determine vascular anatomy
and arterial variants. Prophylactic embolization of nontar-
get vessels was performed to avoid nontarget deposition of
microspheres.
99Tc-macroaggregated albumin was used to
assess lung shunt fraction and splanchnic shunting.
The
90Y radioembolization dose administered to the
target site was calculated using the following formula
(Eq. 1):
DG y ðÞ ¼ A GBq ðÞ   50 1   LSF ðÞ   1    R ðÞ ½  =M kg ðÞ ;
ð1Þ
where D is the dose administered to the target site, A is the
actual activity delivered to the site, LSF is the lung shunt
fraction, R is the residual activity in the vial, and M is the
mass of the area infused [1]. The body surface area method
of dose calculation, which requires calculations of the
volume of the liver and the tumors to be treated, can also be
used [1]. The calculated dose was based on the liver vol-
ume and percentage of the lobe being treated that was
occupied by tumor. For these determinations, baseline CT
obtained within 1 month of treatment was initially ana-
lyzed volumetrically. If repeated treatments were to be
performed, the dose calculations were based on follow-up
CT obtained within 1 month before a given treatment. The
ordered and administered doses were recorded and
retrospectively tabulated for comparison with the other
measured indices.
Multiphasic Abdominal CT
Details of the CT scan protocols are listed in Table 2.
Baseline four-phase (nonenhanced, arterial, portal venous,
and delayed phase) contrast-enhanced CT images were
obtained within 1 month before radioembolization. Four-
phase, contrast-enhanced CT image was also acquired
1 month after treatment to assess response to therapy and
then every 3 months while the patient was undergoing
radioembolization treatments. To determine if these volu-
metric measurements might be used for early prediction of
response, we choose to evaluate volumes from CT images
obtained 1 month after treatment. Digital imaging and
communications in medicine (DICOM)-format images
obtained for baseline and 1-month follow-up CT images
were then used for retrospective application of our semi-
automated segmentation software for the volumetric anal-
ysis of whole-tumor and tumor-necrosis measurements. All
images were deidentiﬁed in accordance with HIPA
requirements; thus, the observers were blinded to patient
demographics.
Table 1 Inclusion and exclusion criteria for radioembolization
Inclusion criteria
Absence of extrahepatic cancer involvement
Child-Pugh class A or B
Performance status: ECOG 0–2, target liver lesion measurable per
RECIST criteria, life expectancy at least 3 months in absence
of treatment, creatinine B 1.50 mg/dl, bilirubin B 2.5 mg/dl,
albumin C 30 g/l, white blood cells C 1.5 9 109/l,
PLT C 50 9 109/l
Exclusion criteria
Ascites
Contraindications to arteriography
Presence of localized or systemic infections
Pregnant (women of child-bearing potential will have a
pregnancy test done)
Known or suspect hypersensitivity to the chemotherapeutics
PLT platelets
Table 2 Technique for multiphasic abdominal CT
Four-phase enhanced CT for evaluation tumor response
Arterial phase
Pitch: 1.375
Collimation: 20 mm
kV: 120
mA noise index of 14 (mA range 100–440)
125 cc nonionic contrast injected at 4 cc/s
Scan timing: Aortic contrast arrival ? 8 s (smart prep used with
evaluation of the abdominal aorta)
Portal venous phase
Pitch: 1.375
Collimation: 20 mm
kV: 120
mA: Noise index of 12 (mA range 100–440
Scan timing: 35 s after arterial phase
Equilibrium phase
Pitch 1.375
Collimation: 20 mm
kV: 120
mA: Auto mA noise index of 16 (mA range 100–440)
Scan timing: 90 s after arterial phase
Matrix size of 512 9 512 pixels
Window parameters were set to the ‘‘abdomen preset’’ with
window level = 25 HU and a window width = 175 HU
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imaging scanners (Lightspeed 16; GE Medical Systems,
Milwaukee, Wisconsin). The arterial phase of enhancement
was used for volumetric analysis of hepatocellular carci-
noma, and the portal phase was used for metastases
because it allowed for the greatest conspicuity. All CT
images obtained during the care of the patient were initially
stored on a Philips iSite Picture Archiving and Commu-
nication System (PACS, Philips Healthcare, Andover,
MA).
Response Assessment
Response according to tumor size was initially assessed
using RECIST criteria, in which the sum of the longest
axial measurement of the target lesions after treatment was
compared with that of the lesions at baseline [4]. When
evaluating correlations of RECIST-based imaging end
points with clinical end points, we chose to combine stable
disease and partial response, i.e.,\20% increase in tumor
size, for Kaplan–Meier analysis. Tumor response was also
assessed according to EASL criteria, which quantiﬁes the
amount of enhancing and necrotic nonenhancing tissue in
the treated lesion [9]. However, the volume of necrotic
tissue was determined using the segmentation analysis
described later in the text rather than using linear mea-
surements. When evaluating correlations of EASL-based
imaging end points with survival end points, we choose a
cut-off point of 10% necrosis in this pilot study. In this
study, tumor necrosis was deﬁned as hypodense nonen-
hancing portions of the tumor as demonstrated on contrast-
enhanced CT image.
Semiautomated Segmentation and Volume
Measurement
All operators were initially trained to use the software and
were supervised by an attending radiologist with 10 years
of experience (W. M.). A set of 10 images, not included for
the actual study, and a scripted instructional session were
used for training purposes.
For the assessment of interobserver/intraobserver
reproducibility to determine liver volumes using the
semiautomated segmentation based on iterative watershed
segmentation (IWS), 23 enhanced CT images were ret-
rospectively analyzed. Three operators (A. G., S. L., and
I. K.) analyzed 23 image sets twice, separated by
1 month’s time, resulting in a total of 138 liver mea-
surements. One operator was a radiology resident (S. L.),
and two operators were senior medical students (I. K. and
A. G.). The operators recorded the volume in cubic mil-
limeters along with the time elapsed in seconds for each
liver measurement.
The liver volumes were also manually measured from
the same CT images on our PACS system using Voxar by
tracing the edge of the liver on each axial slice and then
summating the areas, as currently performed clinically.
Measurements made using the semiautomated segmenta-
tion software and Voxar-based manual tracing techniques
were also compared. The time required to make these
measurements was compared. Voxar is a commercially
available (Barco, Brussels Belgium), FDA-approved, three-
dimensional segmentation software incorporated in our
Stentor iSite (Stentor, San Francisco, CA) PACS system.
The segmentation software (www.pasa.nhs.uk/pasa/doc)
uses ‘‘a number of proprietary techniques’’ to segment the
volume of the selected tissue of interest.
To determine intraobserver/interobserver reproducibility
when measuring whole-tumor, viable-tumor, and necrotic-
tumor volume, three operators (W. M., S. L., and I. K.)
analyzed 23 image sets twice, separated by 1 month’s time,
resulting in a total of 138 tumor measurements.
Long-axis measurements of these tumors were also
determined, as described by RECIST criteria, by two radi-
ology residents (P. S. and J. F.) and compared with whole-
tumor and necrotic-tumor volumes as well as survival.
Survival statistics were obtained from the electronic medi-
cal record (EMR) (V. S.). Twenty-one patients who had
gone radioembolization were included in the assessment for
correlation between volumetric and linear measurements as
well as survival outcomes. Two patients were not included
because they were lost to follow-up; they moved residence
shortly after radioembolization. All observers were blinded
to patient identity because images were deidentiﬁed, and
observers recording survival times were blinded to tumor
measurements. When evaluating responses, making com-
parisons with survival outcomes, and comparing tumor
measurements, we analyzed enhanced baseline CT images
obtained within 1 month before each radioembolization and
follow-up enhanced CT images obtained 1 month after each
radioembolization. Survival was deﬁned as the date of
diagnosis to the date of death and from the date of the ﬁrst
radioembolization treatment to the date of death as obtained
retrospectively from the EMR.
Semiautomated Measurement of Hepatic and Tumor
Volumes
Our semiautomated segmentation software was developed
on a Windows XP (Microsoft Corporation, Redmond, WA)
workstation with the MatLab programming language
(version R2007a; The MathWorks, Natick, MA). The
program was run on an HP Pavilion dv1000 Laptop with a
1.5-GHz processor, 2 GB RAM, and an 80-GB hard drive
(Hewlett Packard, Palo Alto, CA). A graphical user inter-
face was implemented. The semiautomated segmentation
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based on IWS [8] and pixel thresholding (PT) [10]. The
IWS algorithm implemented ﬁrst used gradient vector ﬂow
transformation of the image for edge enhancement, which
was followed by a region-growing method, analogous to
‘‘ﬂooding’’ the gradient vector ﬂow map. Liver and tumor
edges were ﬁnally determined from subsequent ridgelines
formed around each basin (local minima). This method was
previously described and validated by Ray et al. [8].
The overall scheme for semiautomated volumetric
measurement of the liver is illustrated in Fig. 1. All of the
image sets were downloaded from PACS onto a personal
computer using the DICOM format. Slices that did not
include liver parenchyma were deleted from the image sets.
As such, each operator performed measurements on the
same set of CT images. Hepatic segmentation was per-
formed by placing a series of markers that deﬁned the
outside of the liver as well as series of markers that deﬁned
a representative sample of the liver parenchyma. The
software automatically connected each marker with a
straight line, creating a polygonal shape. On each axial
image, the operators had the option of checking their work
by way of an output image (Fig. 2), or to continue to the
next set of images. The operators had the ability to delete,
add, or move any marker at any time. When all image
markers were set, the program added the individual slice
volumes, and total volume was recorded. The time from
loading DICOM images onto the program until output of
total volume was recorded.
Semiautomated Measurement of Whole-Tumor,
Viable-Enhancing Tumor, and Necrotic-Nonenhancing
Tumor Volumes
Segmentation of whole tumor volume was performed by
placing a series of markers that deﬁned the liver paren-
chyma outside of the tumor as well as a series of markers
that deﬁned a representative sample of the tumor. The
software automatically connected each marker with a
straight line, creating a polygonal shape for initialization of
the segmentation routine (Fig. 3A). On each axial image,
the operators had the option of checking their work by way
of an output image or continuing to the next set of images.
The operators had the ability to delete, add, or move any
marker at any time. When all image markers were set and
the boundaries determined, the program added the indi-
vidual slice volumes, and total volume was recorded.
The IWS algorithm calculated the whole-tumor volume
(enhancing and nonenhancing) (Fig. 3A–C). This was
Fig. 1 Overview of IWS-based semiautomated measurement of liver
volumes
Fig. 2 (Left) Enhanced axial
CT image through the abdomen
with observer-set markers
deﬁning the outside of the liver
and internal markers deﬁning a
representative sample of liver
parenchyma. (Right) Image
output post-IWS processing
shows the estimated perimeter
of the liver
Fig. 3 A IWS operator sets internal and external markers results in B outline of whole tumor edge. C Image mask of whole tumor results in
D threshold image to distinguish enhancing tumor from necrosis
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region of normal parenchyma and the enhancing portion or
necrotic nonenhancing portion of the tumor were included
in separate regions of interest. The histogram of pixel
attenuation value was evaluated. The formula for selecting
pixel attenuation values was as follows (Eq. 2):
x ¼ mean þ std dev   multiplier factor ðÞ ; ð2Þ
where x is the cut-off pixel value. All pixel values[x are
countedasenhancingviabletumor,meanistheaveragepixel
value from a sample region of normal adjacent background
parenchyma, andstd_devisthe SD fromthe samesample. If
weassumednormal/Gaussiandistributionofthepixelvalues
of normal parenchyma, and we took all pixels with values
[xmultipliedbyafactorofC3,99%ofthepixelattenuation
values selected were higher (or more dense) than adjacent
normal parenchyma. In practice, the normal parenchyma
samplesarenotinperfectnormal/Gaussiandistribution.The
multiplier factor, which best distinguishes enhancing viable
tumor from necrosis, was chosen by the operator. Necrosis
volume = whole tumor volume - viable enhanced tumor
volume(Fig. 3C,D).Thepercentagechangeofeachvolume
was obtained by comparing volumes measured on pre-
radioembolization baseline CT image with CT image
obtained 1 month after radioembolization. Thus, a negative
%changerepresentsreductioninvolume.Targetlesionsthat
underwent radioembolization were identiﬁed and measured;
untreated lesions were not included in this analysis because
treatment was usually lobar.
Statistical Analysis
Intraobserver/Interobserver Reproducibility of Liver
Volumes
To determine intraoperator reproducibility of measure-
ments of whole-liver volumes using the IWS-based semi-
automated method, we used two-sided Wilcoxon signed-
rank test to assess whether the population median of the
difference in whole-liver volume measurement between the
two trials approached zero.
For interoperator reproducibility of the described volu-
metric method, we computed the ICC among three opera-
tors [11]. We also constructed a Bland–Altman plot [12]
between operators, in which the graphs were assigned the
mean of the two liver volumes, as measured by the two
operators, as the abscissa (x-axis) value and the difference
between the two liver volumes as the ordinate (y-axis)
value.
The time to complete each measurement was recorded
for each method. Friedman’s test was used to compare the
time required for each volumetric measurement among the
three operators.
Intraobserver/Interobserver Reproducibility of Whole-,
Viable-, and Necrotic-Tumor Volume Measurements
For intraoperator reproducibility of measurements, we used
two-sided Wilcoxon signed-rank test to assess whether the
population median of the differences in each volumetric
measurement between the ﬁrst and second measurements
approached zero.
To determine interoperator reproducibility for each
volumetric measurement, we computed the ICC among
three operators [11]. We also constructed a Bland–Altman
plot for each volumetric measurement between two oper-
ators, in which the graph assigned the mean of measure-
ments, as measured by the two operators, as the abscissa
(x-axis) value and the difference between the two liver
volumes as the ordinate (y-axis) value (Fig. 3)[ 12].
Association of Delivered
90Y Radiation Dose
and Change in Whole-Tumor Volume, Tumor-Necrosis
Volume, and Linear Tumor Measurements
We used linear regression with MM (maximum likelihood
type) estimation, a combination of high breakdown value
estimation and efﬁcient estimation introduced by Yohai
[13], to study the associations between the delivered dose,
change in necrosis, change in linear measurements, and
change in whole tumor.
Correlation of Imaging-Based End Points with Survival
To explore whether each of the variables, i.e., radiation
dose change in necrosis, change in RECIST score, and
change in whole tumor, was statistically signiﬁcantly
associated with the survival time, we used the Cox pro-
portional hazards model [14].
Two-sided log-rank test was used to compare the survival
distributions, i.e., since diagnosis and since treatment,
betweenthegroupofpatientswithdelivereddose,thegroupof
patients with\10% versus C10% change in necrotic tumor
volume,the groupofpatientswithchangeofsummatedlong-
axismeasurements\20%orC20%,andthegroupofpatients
with change of whole tumor volume\20% versus C20%. In
addition,Kaplan–Meiersurvivalcurveswerecalculated[15].
Results
Hepatic Volume
Intraoperator Reproducibility
The average measured liver volume using the semiauto-
mated segmentation was 2481.92 ± 1662.98 cc (Table 3).
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between the ﬁrst and second volume measurements (in
cubic centimeters). Measurements from each of the three
observers were analyzed separately. For each observer,
two-sided Wilcoxon signed-rank test was performed to
determine if the population median of the volume differ-
ence approached zero. Observers no. 2 and no. 3 had
p-values of 0.24 and 0.30, respectively, indicating that the
median difference between trials was not different from
zero. Observer no. 1 had a p-value of 0.046, indicating that
there was a difference between volume measurements for
the two trials that was barely statistically signiﬁcant.
Interoperator Reproducibility
For each measurement, the ICC [11] among the three
observers was computed. For the ﬁrst and second mea-
surements, the values were 0.984 and 0.992, respectively.
Both of these values were high, indicating that the volume
measurements for a given image were consistent across all
three observers. The higher ICC value for the second
measurement indicated that the three observers’ second set
of measurements was more consistent than the ﬁrst set of
measurements, suggesting some learning curve. The
Bland–Altman [12] plots between any two operators also
suggested interoperator reproducibility (Fig. 4).
There was no statistically signiﬁcant change in speed of
acquisition when making measurements the ﬁrst and sec-
ond time with either the automated or manual approach
(Table 4). For each observer, two-sided Wilcoxon signed-
rank test was performed to determine if the population
median of the time difference between measurements
approached zero (p = 0.628, 0.1000, and 0.427 for
observers no. 1 through 3, respectively).
Comparison of Manual Versus Semiautomated
Segmentation of Liver Volume
In addition to determining interobserver/intraobserver
reproducibility of measurements using this semiautomated
segmentation, the segmentation software was compared
with our current standard manual tracing tools using the
Voxar work station (Table 3). Measurements of liver vol-
ume, as well as the time required to complete the mea-
surements, were evaluated by calculating the ICC [11]
between the two techniques. An ICC of 0.868 indicated
that the measurements of whole liver by the two techniques
were similar. Bland–Altman [12] plot between the two
techniques also suggested similarity of liver volume
(Fig. 5).
Signiﬁcantly less time was required to take volumetric
liver measurements using the semiautomated software
compared with current manual tracing of the edge of the
liver on each axial CT image (p-value of two-sided
Wilcoxon signed-rank test\0.0001) (Table 4). An ICC of
0.088 also indicated a signiﬁcant difference in the time
required to measure whole-liver volumes using the two
techniques [11]. Bland–Altman [12] plots between the two
techniques also demonstrated differences in the time
required to make these measurements (Fig. 6).
Intraobserver/Interobserver Reproducibility
for Measurements of Whole-Tumor and Necrotic-Tumor
Volumes
There was good reproducibility of volumetric measure-
ments of whole-tumor and necrotic-tumor volume applied
to tumors that had undergone radioembolization, with no
signiﬁcant difference between the ﬁrst and second mea-
surements within any of the three observers (p[0.05).
However, one observer demonstrated a statistically sig-
niﬁcant difference between the two measurements of viable
enhancing tumor (p = 0.004).
To determine interobserver reproducibility for each
volumetric measurement, the ICC among the three
observers was computed [11]. Furthermore, Bland–Altman
plots between any two operators were evaluated [12]. The
ICC among the three observers for the ﬁrst and second
measurements of whole tumor volume was 0.988 and
0.992, respectively. The ICC among the three observers for
the ﬁrst and second measurements of the volume of non-
enhancing hypodense tumor necrosis was 0.912 and 0.951,
respectively. The ICC among the three observers for the
ﬁrst and second measurement of the volume of viable
enhancing tumor was 0.899 and 0.911, respectively.
Comparisons of Linear and Volumetric Tumor
Measurements
There was a statistically signiﬁcant positive association
between the change in linear measurements of tumors, as
deﬁned by RECIST criteria (as an independent variable),
Table 3 Whole-liver volumes determined with IWS versus Voxar
Variable N Mean SD SE Median Min Max
Volume of whole liver measured by IWS 23 2481.9 1662.9 354.5 1913.2 1312.1 7577
Volume of whole liver measured by Voxar 23 2419.7 1596.4 340.3 1804.7 1311.32 7148.2
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able) (p\0.0001). However, these linear tumor measure-
ments did not correlate with the volume of necrotic-tumor
tissue (p[0.05).
Correlation of Radioembolization Dose,
Tumor Response, and Survival
Comparisons of measurements were made between base-
line CT image obtained within 1 month before a given
treatment and follow-up CT image obtained 1 month after
a treatment to determine if these measurements could be
used for early prediction of response and survival. A
summary of the change in necrotic tumor volume, linear
tumor measurements, and whole-tumor volumes, as well as
delivered
90Y dose, is listed in Table 5. In this small pilot
study aimed at evaluating observer reproducibility for this
volumetric analysis tool, we also attempted to explore the
possible clinical utility of this approach.
90Y radiation dose delivered during radioembolization
did not correlate with subsequent change in tumor mea-
surements, including linear measurements (p = 0.3025),
Fig. 4 Bland–Altman plots for
interoperator reproducibility.
Each point represents a single
patient image set, plotting on
the x-axis (liver volume
measured by operator A and
liver volume measured by
operator B versus the y-axis
(liver volumetric measured by
operator A and liver volumetric
measured by operator B). The
degree of dispersion around the
horizontal axis represents
variability in the measurements.
Liver volumes are in cubic
centimeters
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123whole-tumor volume (p = 0.4041), and tumor-necrosis
volume (p = 0.6743). However, such is not the aim of this
article. Our patient population is likely too small for this
determination. Response and survival is dependent on a
large number of factors. For example, survival can be
affected when there is a difference in dose administration
between tumor and normal (partition model dosimetry).
Using the Cox proportional hazards model, we deter-
mined that administered
90Y dose, overall change in single
long-axis diameter measurements, whole-tumor volume,
and necrotic-tumor volume did not correlate with survival
outcomes as measured from time of diagnosis or from time
of treatment (p[0.05 in all instances). However, when
constructing Kaplan–Meier curves, there was a statistically
signiﬁcant difference in survival time since diagnosis
between the group of patients with change in necrosis
\10% compared with those with change in necrosis C10%
(p-value of log-rank test = 0.0472) (Fig. 7). Finally, there
was no statistically signiﬁcant difference in survival times
when comparing the group of patients with change of
summated long-axis measurements \20% or C20% and
those with change of whole tumor volume \20% versus
C20% (p-value of log-rank test = 0.3198 and 0.4506,
respectively).
Discussion
There exists an extensive body of evidence demonstrating
the palliative and therapeutic efﬁcacy of local regional
catheter-directed therapies, such as radioembolization, for
the treatment of hepatocellular carcinoma as well as
hepatic metastases [1]. The optimal approach for imaging-
based follow-up after radioembolization is a subject of
much ongoing research [5, 16]. The current study describes
a technique for semiautomated volumetric assessment of
the whole tumor as well as the viable enhancing and
nonenhancing necrotic or nonperfused portions of the
tumor. Good reproducibility of each of these measurements
was demonstrated. This type of analysis might allow early
prediction of response.
Furthermore, radioembolization preprocedural planning
and dose determination is dependent on calculations of
liver volume and the percentage of liver occupied by
tumor. Organ and tumor volumetric measurements, as seen
on CT images, are usually performed by manual tracing of
Table 4 Time for whole-liver volume measurements with IWS versus Voxar
Variable N Mean SD SE Median Min Max
Time to measure whole liver by IWS (s) 23 395 122.82 26.185 394 246 745
Time to measure whole liver by Voxar (s) 23 560.27 118.35 25.233 531.5 411 832
Fig. 5 Bland–Altman plot comparing measurements of whole-liver
volumes using semiautomated IWS segmentation versus manual edge
tracing using Voxar
Fig. 6 Bland–Altman plot comparing time taken to make measure-
ments of whole-liver volumes using semiautomated IWS segmenta-
tion versus manual edge tracing using Voxar
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123boundaries and summation of the areas on each section.
These manual methods of liver-volume segmentation are
time consuming and laborious. They have been reported to
take anywhere from 19.0 to 46.5 min [2, 3] In our study,
the IWS-based semiautomated method required an average
of 6.0 min across all observers, 3.2- to 7.7-fold faster than
reported manual methods. We found manual-based tracing
using Voxar to take signiﬁcantly longer to complete. In
practical terms, the method represents an improvement
compared with manual methods because it only requires
the approximate creation of a rough polygon bordering
around a tissue of interest instead of a labor-intensive
‘‘hand-drawn’’ accurate border.
It has been suggested that measuring tumor response
with linear diameters alone may be limited because tumor
necrosis is not taken into account. [9]. This is particularly
true when evaluating response to local regional therapies,
such as radioembolization [17]. Characteristics of tumor
enhancement after radioembolization were studied by Riaz
et al. [18] and Ibrahim et al. [19]. Enhancement charac-
teristics were not included in the current study. However,
tumor necrosis is often patchy and irregular in distribution,
making usual linear measurements difﬁcult. In addition,
response to local regional therapy does not necessarily
correspond with an immediate decrease in size of the
treated lesion. The degree of necrosis seen on imaging is an
important component in assessing early response to treat-
ment [9].
The efﬁcacy of transarterial chemoembolization and
radiofrequency ablation has been evaluated by estimating
the degree of necrosis on CT that correlated with the degree
of necrosis on pathologic examination [20]. Furthermore,
actual tumor necrosis within resected tumors corresponded
to areas of nonenhancing tumor necrosis on post-
radioembolization CT imaging [18]. In this small pilot
study, Kaplan–Meier curves suggested correlation of tumor
necrotic volume and subsequent survival when a [10%
increase in tumor-necrosis volume was demonstrated on
enhanced CT 1 month after radioembolization. A cut-off
point of 10% increase in necrosis was chosen arbitrarily. In
larger studies, different cut-off points might be evaluated
for their predictive value. It is interesting that there was no
statistically signiﬁcant difference in survival times when
comparing the group of patients with change of summated
long-axis measurements \20% or C20% and those with
change of whole tumor volume \20% versus C20%
(p-value of log-rank test = 0.3198 and 0.4506, respec-
tively). This further suggests shortcomings of RECIST
criteria and supports the use of EASL assessment criteria
focused on tumor necrosis when evaluating response to
radioembolization [9]. However, to further evaluate the
predictive value of volumetric change analysis, this tech-
nique should be applied in a large prospective clinical trial,
as suggested by Sargent et al. [21].
It has been shown that necrosis measurements allowed
signiﬁcantly earlier detection of response relative to size
criteria (World Health Organization and RECIST) because
necrosis usually occurs shortly after treatment and before
there is a decrease in lesion size. Miller et al. demonstrated
necrosis criteria to be more reliable than size criteria for
response evaluation in initial follow-up examinations after
treatment [22]. The early identiﬁcation of nonresponders
allowed a prompt change to another therapy, such as
chemoembolization [22]. Miller et al. demonstrated a
median time to response of 29 days when evaluating tumor
necrosis with enhanced CT. In the current study, the ﬁrst
follow-up imaging was obtained at 1 month to determine if
results at this early time point might correlate with
Table 5 Summary of tumor measurements
Variable N Mean SD SE Median Min Max
90Y Dose (mCi) 23 36.7 15.3 3.3 32.8 16.1 66.7
Change in necrotic volume (%) 23 -31.2 77.2 16.8 -26.131 -246.17 45.2473
Change in linear measurements (%) 23 3.223 27.9 6.1 -7.5471 -30.882 94.7619
Change in whole tumor volume (%) 23 41.93 135.72 29.6 -19.894 -98.164 402.048
Fig. 7 Kaplan–Meier curves of survival time since diagnosis for the
group of patients with change in necrosis \10% and the group of
patients with change in necrosis C10%
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123subsequent survival. Functional MRI obtained at 1 month
after radioembolization has been shown to predict response
and correlate with survival [23]. However, it is not known
if earlier or later imaging could demonstrate tumor
response, which might be more predictive of treatment
efﬁcacy and survival outcomes.
In the case of chemoembolization, it has been shown that
the extent of tumor necrosis, as demonstrated on CT 1 to
3 weeks after treatment, correlated with the extent of iodi-
nized oil retention [24]. In our pilot study, we did not ﬁnd a
correlation between the delivered dose of
90Y and sub-
sequent tumor necrosis, tumor response, or survival. How-
ever, the delivered dose was based on hepatic lobar volume
and percentage of tumor occupied by tumor, unlike the dose
of chemotherapy delivered during chemoembolization.
Intraobserver reproducibility may be somewhat less than
desirable when measuring viable enhancing tumor. One
observer had a signiﬁcant difference between the ﬁrst and
second set of measurements (p = 0.004). This occurred
because the enhanced tumor portions are not different
enough from attenuation values of the adjacent liver paren-
chyma, particularly in less-deﬁned nonencapsulated and
inﬁltrating tumors. Nevertheless, good interobserver repro-
ducibility was demonstrated. Hunt et al. also demonstrated
that contrast-enhanced CT or MRI obtained approximately
1 month after TACE and before transplantation was asso-
ciatedwith a high error rate for the detection of viable tumor
compared with histopathology [16]. Additional preprocess-
ing may allow improved quantitation of the enhancing por-
tion of the tumor. It is also true that the current standard of
linear measurements of tumor diameters is limited when the
tumor margins are ill deﬁned, as with an inﬁltrating tumor.
This retrospective pilot study is limited by small sample
size; variation in the patient population related to clinical
presentation; tumor type, size, and number; and number of
treatments. The sample size was too small to allow for
stratiﬁcation based on the factors that would affect survival
outcomes. Determinants of therapeutic response are com-
plicated and numerous and were not taken into account.
Imaging-based tumor response does not by itself suggest
clinically meaningful therapeutic efﬁcacy unless there is
also improvement in other clinical end points, such as
survival or even quality of life. We therefore attempted
initial assessment to determine if there was any correlation
of these imaging end points with survival time for these
patients. The analysis tool was applied retrospectively to
CT studies for patients who had previously undergone their
course of treatment. These analysis tools next need to be
applied in a large, prospective, randomized clinical trial to
evaluate how volumetric assessment of whole-tumor and
tumor-necrosis volumes might predict survival outcomes.
Once validated, volumetric analysis may then be used as an
early surrogate marker of response in clinical trials and
applied to clinical care decisions [21].
The current study design was not meant to evaluate
accuracy. We previously demonstrated accuracy of the IWS
approach using phantoms [8]. Others have compared imag-
ing-based volumetric measurements of tumors, organs, and
necrosis with resected tissue. In our medical center, few
transplants are performed, and very few hepatic tumors are
resected after local therapy. Therefore, we could not be
certain that hypodense tumor tissue was necrotic or hypop-
erfused. However, a number of studies have demonstrated
that ‘‘necrotic’’ tumor tissue on CT corresponded to actual
tumor necrosis of subsequently resected tissue [18, 20].
A possible limitation of the semiautomated approach is
that the operator must select the desired computer-gener-
ated boundaries. This can become a challenge at times,
especially considering partial volume effects in the
boundary areas (Fig. 8)[ 3]. Even when making linear
manual whole-tumor measurements, the radiologist must
determine what he or she thinks is the edge of the lesion.
This may be difﬁcult, particularly in the case of inﬁltrating
ill-deﬁned lesions, thus introducing operator-dependent
error and interobserver/intraobserver variability, which
decrease with semiautomated segmentation approaches. A
beneﬁt of this semiautomated segmentation, compared with
a completely automated method, is that the operator has the
ability to accept, decline, or modify the computer-gener-
ated outline. Such ﬂexibility is often needed when
Fig. 8 (Left) Nonenhanced CT
axial image through the
abdomen with observer-set
markers placed on a liver that
directly abuts the stomach.
(Right) Image output after IWS
processing shows an uncertain
border between liver and
stomach, a problem likely
attributed to partial volume
averaging
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123measuring volumes of the liver in close proximity to
adjacent structures having similar Hounsﬁeld units, such as
the stomach or heart (Fig. 8).
A large number of segmentation approaches have been
described for various applications [25–28]. In the approach
presented, we did not use geometric modeling, such as
spheres, to obtain segmentation maps, as described by
Salvi et al. [28]. We did not use shape constraint to prevent
the region growing from leakage into surrounding tissues
of similar characteristics, as described by Zhoa et al. [27].
However, this approach may be helpful when the tumor is
inﬁltrative or when the border is not easily discernable
from adjacent parenchyma.
Another limitation occurs when trying to measure lobes
of the liver separated by the fat-containing falciform liga-
ment. This problem is currently approached by either
bridging the split-liver areas (Fig. 9), or by measuring each
segment separately. Lobar liver volumes were not addres-
sed in this study. The measurement of segmental or lobar
liver volumes using the proposed method can be per-
formed. The volume of each lobe could be calculated
separately by including only the lobe of interest in the outer
boundary.
Several sources of variability affected reproducibility
and accuracy in this study. The operators decided the
manual placement of the inner and outer boundary markers.
The best results were obtained when the inner boundary
included a large and representative sample of liver paren-
chyma and the outer boundary excluded the liver paren-
chyma in its entirety. The operators could have also chosen
to exclude nonhepatic tissue from the measurement. This is
performed by placing an outer marker directly over the
middle of unwanted tissue. Figure 2 demonstrates exclu-
sion of the inferior vena cava by way of this technique.
In conclusion, good interobserver/intraobserver observer
reproducibility of semiautomated volumetric assessment of
liver, whole-tumor, and necrotic-tumor volumes is dem-
onstrated. The technique is faster than traditional manual
tracing methods. Although the described method of deter-
mining liver volume was tested on patients who were
subsequently treated by radioembolization, the approach
can be applied for planning liver surgery [29], resection
[30], or liver transplantation [31]. This small pilot study
may suggest that volumetric assessment of tumor necrosis
could allow early prediction of subsequent survival out-
comes. However, this must be further validated in larger
prospective studies.
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